Develops atacicept and other medicines for serious immunological diseases, including autoimmune kidney diseases and BK virus infections, for patients with those conditions.
10-K for FY2025, filed Feb 26, 2026
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$93.7MView ↗
8-K, filed Aug 10, 2026
Final efficacy analysis from the ORIGIN 3 trial expected in Q3 2026View ↗
8-K, filed Jun 2, 2026
On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food…View ↗
Development priorities
The older report planned a lupus nephritis trial and delayed resources for it and the BK-virus program; the latest report focuses on completing atacicept’s IgAN development while evaluating further development of the BK-virus program.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Feb 26, 2026In January 2023, we announced our plan to prioritize and focus our current resources on the advancement of atacicept in IgAN into a pivotal…View ↗
Competes with Asahi Kasei, Otsuka Pharmaceuticals, Novartis, Travere Therapeutics, Roche, Ionis, Vertex, AstraZeneca, Biogen, Takeda, Arrowhead Pharmaceuticals, BeOne Medicines, Climb Bio, Walden Biosciences, Sanofi, Eli Lilly, Astellas, Boehringer Ingelheim, Memo Therapeutics, and Aurinia Pharmaceuticals
10-K for FY2025, filed Feb 26, 2026Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the…View ↗
Loading...